Mitochondrial Dynamics in Cardiovascular Medicine

Dr. Gaetano Santulli received his MD and PhD at the University of Naples “Federico II”. A physician scientist, Dr. Santulli completed his postdoctoral training at Columbia University Medical Center in New York City, supported by an AHA fellowship and a Scientist Development Grant. Cardiologist, he authored more than 100 publications, including peer-reviewed articles in high impact journals, book chapters, and medical books. He is currently a faculty member of Columbia University. He lives in Manhattan.Dr. Santulli’s expertise comprises both clinical and basic research topics, including hypertension, diabetes, angiogenesis, heart failure, arrhythmias, vascular disorders, and skeletal muscle disease. He is a member of several international academic societies, including New York Academy of Sciences, American Heart Association (AHA), American Diabetes Association, European Society of Cardiology, Endocrine Society, American Association for the Advancement of Science, European Association of Heart Failure, European Association of Echocardiography, Acute Cardiovascular Care Association, European Association of Percutaneous Cardiovascular Interventions. He serves on the Editorial Boards of numerous medical Journals

Cardiac metabolic remodelling:  hypoxia vs. failure .- Nitric Oxide and Mitochondrial Biogenesis .- Nitrite-nitric oxide signaling and cardioprotection .- Mitochondrial mutations in cardiac disorders .- Mitochondria and cardiac hypertrophy .- Functional implications of the clustering of cardiac mitochondria .- Mechanistic role of thioredoxin 2 in heart failure .- Mitochondrial bioenergetics during ischemia/reperfusion .- Peripheral blood mitochondrial DNA and myocardial function .- Mitochondria and angiogenesis .- Mitochondrial oxidative stress and atherosclerosis .- Apolipoproteins and mitochondrial function .- Mitochondria and glucose homeostasis .- Insulin resistance and mitochondrial dysfunction .- Mitochondria and cardiorenal syndrome .- Mitochondrial damage in kidney disease .- Prohibitin-2 and kidney function .- Mitochondrial heteroplasmy .- Mitochondrial transplantation.